Peri-operative metabolomic alterations predict post-operative complications and hospital stay in colorectal cancer patients.
[PURPOSE] This study aimed to explore whether the peri-operative metabolomics correlates with post-operative complications and hospital stay in colorectal cancer (CRC) patients.
APA
Liu XY, Shu XP, et al. (2025). Peri-operative metabolomic alterations predict post-operative complications and hospital stay in colorectal cancer patients.. International journal of surgery (London, England). https://doi.org/10.1097/JS9.0000000000004500
MLA
Liu XY, et al.. "Peri-operative metabolomic alterations predict post-operative complications and hospital stay in colorectal cancer patients.." International journal of surgery (London, England), 2025.
PMID
41376476
Abstract
[PURPOSE] This study aimed to explore whether the peri-operative metabolomics correlates with post-operative complications and hospital stay in colorectal cancer (CRC) patients.
[MATERIALS AND METHODS] In this observational study, we collected information of the CRC patients enrolled from Jan 2024 to Dec 2024. We evaluated the pre-operative and ratios of post-operative to pre-operative metabolomic profiles to investigate their associations with post-operative complications and length of hospital stay. Logistic regression and linear regression were used to find independent indicators for post-operative complications and length of hospital stay.
[RESULTS] A total of 243 CRC patients was included in this study. Prolonged surgical time, comorbidity of hypertension, increased tumor size, pre-operative 2-Aminobutyric acid, pre-operative glucose, higher levels of creatine ratio and H2TG ratio were independently associated with a higher risk of post-operative complications. As for post-operative hospital stay, surgical time, V3PL ratio, L4TG ratio, and 2-Hydroxybutyric acid ratio were independent predictors. Moreover, integrating both clinical and metabolic profiles demonstrated the best predictive performance for post-operative complications, and length of hospital stay.
[CONCLUSION] Peri-operative metabolomics were significantly associated with post-operative complications and hospital stay in CRC patients. Integrating metabolic biomarkers with clinical parameters demonstrated the best predictive performance.
[MATERIALS AND METHODS] In this observational study, we collected information of the CRC patients enrolled from Jan 2024 to Dec 2024. We evaluated the pre-operative and ratios of post-operative to pre-operative metabolomic profiles to investigate their associations with post-operative complications and length of hospital stay. Logistic regression and linear regression were used to find independent indicators for post-operative complications and length of hospital stay.
[RESULTS] A total of 243 CRC patients was included in this study. Prolonged surgical time, comorbidity of hypertension, increased tumor size, pre-operative 2-Aminobutyric acid, pre-operative glucose, higher levels of creatine ratio and H2TG ratio were independently associated with a higher risk of post-operative complications. As for post-operative hospital stay, surgical time, V3PL ratio, L4TG ratio, and 2-Hydroxybutyric acid ratio were independent predictors. Moreover, integrating both clinical and metabolic profiles demonstrated the best predictive performance for post-operative complications, and length of hospital stay.
[CONCLUSION] Peri-operative metabolomics were significantly associated with post-operative complications and hospital stay in CRC patients. Integrating metabolic biomarkers with clinical parameters demonstrated the best predictive performance.
같은 제1저자의 인용 많은 논문 (5)
- Chronic social defeat stress accelerates lung cancer progression and induces hippocampal metabolic dysregulation in a duration-optimized comorbid model.
- Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort.
- Development and validation of a nomogram incorporating dietary factors for predicting -negative early gastric cancer risk.
- Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
- Reactive oxygen species-responsive micelles targeting activated hepatic stellate cells for treating liver fibrosis.